Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
- 2 November 2015
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 37 (12), 2751-2769
- https://doi.org/10.1016/j.clinthera.2015.09.004
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic DiseasesMediators of Inflammation, 2013
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial HypobetalipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic miceJCI Insight, 2006
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteAmerican Journal of Human Genetics, 2006
- Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genesProceedings of the National Academy of Sciences of the United States of America, 2003
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003